Ref. No.: F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated 01.11.2013

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in,
rmsc.drugprocurement@yahoo.in

E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Ending on 31.12.2015)

!! सर्वे सन्तु निरामयाः!!

LAST DATE OF SUBMISSION OF ONLINE BIDS: 10.12.2013 Upto 1:00 PM

Ministry of Health & Family Welfare
Government of Rajasthan
RMSCL
"Mukhyamantri Nishulak DavaYojana"
'D' Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India
Tel No: 0141-2228066, 2228064, E-mail: rmsc@nic.in

Ref. No.: F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated 01.11.2013

Notice Inviting E-Bids

E-bids are invited upto 1.00 PM of 10.12.2013 from approved Drugs Testing Laboratories situated in the state of Gujarat, Rajasthan, M.P., Haryana, Maharashtra, Himachal Pradesh and NCR of Delhi for analysis of Drugs. (Ending on 31.12.2015) Details may be seen in the Bidding Documents at our office or at the website of State Public procurement Portal http://sppp.raj.nic.in, www.dipronline.org, http://eproc.rajasthan.gov.in. , www.rmsc.nic.in and may be downloaded from there.

Executive Director (Procurement)
RMSCL

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

RAJASTHAN

E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Ending on 31.12.2015)

Bid Reference	**:**	F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated :01.11.2013
Pre- bid conference		: **14.11.2013 at 11.00 A.M.** (RMSC meeting Hall)
Date and time for downloading bid document		: **11.11.2013 from 6.00 PM**
Last date and time for Downloading bid document		: **09.12.2013 at 6.00 PM**
Last date and time of submission of online bids		: **10.12.2013 at 1.00 PM**
Date and time of opening of Online technical bids		: **10.12.2013 at 2.30 PM**
Cost of the Bid Document		: **Rs. 2000/-**
RISL Processing Fees		: **Rs. 1000/-**
EMD		: Rs. 20000/-

RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

E-BID FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE TEST AND ANALYSIS OF DRUGS (Ending on 31.12.2015)

"CONFIDENTIALITY IS THE ESSENCE OF THIS BID"

1. LAST DATE FOR RECEIPT OF BIDS, BID FEES, EMD, RISL PROCESSING FEES AND EMPANELMENT FEES

a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Will Be Received Till 1.00 PM on 10.12.2013 By The Rajasthan Medical Services Corporation Ltd, For The Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Ending on 31.12.2015)

b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Earnest Money deposit.

c) The e-Bids will be received on web-portal of e-procurement of GoR. Every Bidder will be required to pay the Bid form fee Rs. 2000.00 for downloaded from the website, EMD as applicable in Bid condition no. **6** and processing fee of Rs.1000.00 of R.I.S.L. through three separate prescribed challans (***format enclosed in Annexure- I)*** in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country upto 09-11.2013 or through D.D. / bankers cheque in favour of M.D. RMSCL (tender fees and EMD), MD, RISL (tender procession fees) physically in the office of RMSC by 1.00 PM on 10.11.2013. The bidders shall submit/upload scanned copy of all the challans in Technical Bid**.** Bids will be opened only after ensuring receipt of Bid fees along with processing fees and EMD. In the absence of Bid fees and processing fees and EMD the Bids will be rejected and will not be opened.

2 **Eligibility Criteria for Empanelment :-**

(1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules thereunder, with three years standing in the test & analysis and the lab shall be entitled for empanelment for the categories of items for which lab is having approval. Bid is invited from approved Drugs Testing Laboratories situated in the state of Gujarat, Rajasthan, M.P., Haryana, Maharashtra, Himachal Pradesh and NCR of Delhi.

(2) The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules thereunder and should hold schedule L-1 certificate or should have NABL accreditation with proper scope of accreditation to undertake testing of drugs, surgical and sutures.

(3) The laboratory should have an average annual turnover of not less than **Rs. 50 Lakhs towards drug, surgical and sutures testing services** for past preceding three years (2010-11, 2011-12, 2012-13).

(4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of at least three government institutions/corporation/reputed manufacturers of drug formulations.

(5) The lab should not stand banned / debarred or blacklisted by any State **or** Central Government Organizations or its central procurement agencies on the due date of bid submission.

(6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and conduct of the laboratory.

(7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with minimum three functional HPLC's.

3 **TECHNICAL BID**

The Bidder must furnish the following in technical bid.

(a) Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be testing at **Annexure-VII)**. **The bidder has to mentioned type of test for each item to be carried out by him, the filled up annexure VII to be submitted with**

technical bid.

(b) The bidders shall submit/upload scanned copy of all the challans in Technical Bid deposited for Bid fees, RISL processing fee and Earnest Money, in case deposited in any branch of PNB throughout country. The required EMD / Tender fees/ RISL fee may be in form of physical D.D./ BC along with letter. D.D. / bankers cheque shall be in favour of M.D. RMSCL (tender fees and EMD), MD, RISL (tender procession fees).

(c) Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.

(d) Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate)/Copy of NABL accreditation with scope for testing of drug formulations.

(e) Documentary evidence of having analysed Drugs for the last three years with a statement in the proforma as given in **Annexure III**.

(f) Attested copy of certificate of registration for service tax.

(g) Non- Conviction Certificate by the State Licensing Authority/ competent authority .

(h) ***Annual turnover statement for 3 year i.e. 2010-11 , 2011-12 and 2012-13 certified by the practising Chartered Accountant.***

(i) ***Copies of the Balance Sheet and Profit and Loss Account for three years i.e. 2010-11 , 2011-12 and 2012-13 duly certified by the practicing Chartered Accountant.***

(j) The following information in the form given **in Annexure IV (a) to IV(d).**

a) The list of qualified personnel employed in the laboratory with proof of their qualifications and relevant approvals.

b) The list of sophisticated instruments available in the laboratory.

c) Micro Biological facilities available in the laboratory.

d) List of Reference Samples along with their date of procurement and quantities.

e) In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared

as "not of standard quality".

k) A declaration in the proforma given in Annexure V duly signed and Notarized.

l) Details of Laboratory in Annexure – VI.

m) A copy of PAN issued by Income Tax Department.

n) **Documentary evidence for the constitution of the company / concern.**

4 PRICE BID :

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only**. **The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be coated separately at last entry of BOQ.**

5 OPENING OF TECHNICAL AND FINANCIAL EVALUATION

1. There after the Bidders found eligible as stated above on the basis of the examination on technical bid, the financial bid will be opened and after scrutiny thereof, including inspection of the laboratory, if required, the acceptable rates for analysis will be decided and communicated.

6 EARNEST MONEY DEPOSIT

The Earnest Money Deposit shall be Rs. 20,000/- The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country up to 09.12.2013 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 1.00 PM on 10.12.2013 Earnest Money Deposit in any other form will not be accepted.

The Bids submitted without sufficient EMD will be summarily rejected. The EMD will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails

within specified time to sign the contract agreement or fails to furnish the security deposit.

7 GENERAL CONDITIONS

1. The details of the Drugs, to be analysed shall be given in **Annexure VII**.
2. The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test should be mentioned in **Annexure-VII**. **However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ. Wherever test are prescribed and their name and methodology for testing are not stated, such lab will not be considered responsive testing for such item.**
3. The rates quoted should be exclusive of taxes.
4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the BID period.
5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
6. The laboratory will not be permitted to outsource any test from other laboratory.
7. RMSCL shall have the right to cause the laboratory to be inspected by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.

8. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.

2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.

9. AGREEMENT

1. The agreement with empanelled laboratories will remain valid up to 31.12.2015. This may be further extended for a further period of three months with mutual consent.
2. All Bidders who are empanelled will have to execute an agreement on a non- judicial stamp paper of value **Rs. 1000 /-** (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The form of agreement will be issued by RMSCL.
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

10. PERFORMANCE SECURITY

1. The successful Bidders shall be required to pay a security deposit of **Rs.50,000/-** ***in the form of demand draft*** at the time of execution of the agreement. **Performance security will be refunded three month after expiry of rate contract subject to successful completion of services.**

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:

   I. 10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)

   II. 21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.

   b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc., (as the case

may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample.

c) **"COMPLIES" or "PASSES" in the result column of the report is treated as incomplete report, if the result has some numerical value.**

d) **Every test report must have remarks either as "Standard Quality" or "Not of Standard Quality". Any ambiguity/cutting in reports will not be accepted (clear mention of "standard quality or not of standard quality" should be stated in bold letters and crossing/cutting of one of these will not be accepted).**

e) Reports should be in A4 size (8.27" X 11.69") paper of good quality.

f) Report should be issued on form 39 and should have S. no. , name of drug sample, code no., batch no., mfg. date, exp. date, description of tests, protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the final results and reason for failure should be highlighted by pink / red highlighters.

g) Reports should be attached along with Spectra / Chromatography data sheets, if applicable and it will be considered incomplete if spectra or chromatograms are not attached.

2. All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / E-mail and the report should be sent along with protocol.

3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of

inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.

4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.
5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Rajasthan Medical Services Corporation Limited Jaipur by Fax or E-mail.
6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust any further testing job to the laboratory based on facts brought out during such inspections.
7. **The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.**
8. **It will be sole discretion of RMSC to allot the samples to any empanelled lab in case when there are more than one lab approved for an item.**

12. PAYM ENT PROVISIONS

1. No advance payment towards any analysis will be made to the empanelled Bidder.
2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.

13. PENALTIES

1. If the successful Bidder fails to execute the agreement and payment of security deposit within the time specified or withdraws the BID after intimation of the acceptance of the BID has been sent to or owing to any other reasons, he is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money Deposit deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to of breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final.

2. Non performance of any BID or empanelment conditions will disqualify a laboratory to participate in the BID for the period as decided by RMSCL.

3. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.

4. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate without assigning any reasons, the empanelment of any laboratory either wholly or in part at one month's notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.

5. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.

6. (i)If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance he shall apply in writing for extension

on occurrence of hindrance but not after the stipulated date of ***furnishing the test report***.

(ii)The Executive Director (QC)/ ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.

(iii)**Extension in testing period:-** In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of ***testing charges*** which the Bidder has failed to submit:-

(a) Delay upto one fourth period of the prescribed testing period; 2.5%

(b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%

(c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%

(d) Delay exceeding three fourth of the prescribed testing period; 10%

Note: Fraction of a day in reckoning period of delay in ***furnish the test report*** shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

(iv) If, at any time during the continuance of this Agreement, the ***laboratory*** has, in the opinion of the Purchaser, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the ***RMSCL*** purely at his discretion for such period as may be considered reasonable. No further representation from the ***laboratory*** will be entertained on this account.

14. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit

price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

(ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

(iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:

The Designation and address of the First Appellate Authority is Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan.

The Designation and address of the Second Appellate Authority is Principal Secretary, Medical, Health & Family Welfare, Govt. of Rajasthan and Chairman, RMSCL.

i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

(a) Determination of need of empanelment;

(b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;

(d) Cancellation of a empanelment process;

(e) Applicability of the provisions of confidentiality.

v. Form of Appeal

(a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.

(b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.

(c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

(a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.

(b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

(i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. <u>COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:</u>

Any person participating in a empanelment process shall-

a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;

b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;

c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;

d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;

e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;

f) Not obstruct any investigation or audit of a procurement process;

g) Disclose conflict of interest, if any; and

h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

a. Have controlling partners/shareholders in common; or

b. Receive or have received any direct or indirect subsidy from any of them; or

c. Have the same legal representative for purposes of the Bid; or

d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or

e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this

does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or

f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or

g. Bidder or any of its affiliates has been hired (or is proposed to be hired0 by the Procuring Entity as engineer-in0chage/ consultant for the contract.

18. JURISDICTION

1. In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.

Managing Director
Rajasthan Medical Services Corporation

Annexure - 1

CAUTION : USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM"

Bank Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ - -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

Customer Copy

punjab national bank

DIST. NO.

Branch

Institute Name: Rajasthan Medical Services Corporation, Jaipur

Institute ID: RMSCJ - A/c No. 2246002100024414

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit: Select any one out of - Tender Fees/EMD/SD/ Tender Processing fees/Others

Mobile No.

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable ₹

Commission ₹ 0 0 0 0 0 - 0 0

Total amount ₹ - -

Amount (in words): ₹ _____

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

ANNEXURE- II
Ref. Clause No. 2 (3), 3(h)

ANNUAL TURN OVER STATEMENT

The Annual Turnover ***(for drugs and medicines including Surgical and sutures testing services)*** of M/s._____for the past three years are given below and certified that the statement is true and correct.

S.No.	Years	Turnover in Lakhs (Rs)
1	2010-11	
2	2011-12	
3	2012-13	
Total		**Rs.** **Lakhs**
Average turnover per annual		**Rs.** **Lakhs**

Date:

Seal:

Siganture of Auditor/
Chartered Accountant
(Name in Capital)

ANNEXURE III
Ref. Clause No: 3 (e)

PROFORMA FOR PERFORMANCE STATE MENT
(for a period of last 3 years)

Name of the Laboratory : _____

Address:_____

_____

Types of Samples Analysed No. of Samples Analysed during

(2010-2011, 2011-12 & 2012-13)

01. Tablets / Capsules / Pessaries/Dry Powders

02. Injectables

03. Liquid Preparations

04. Ointments / Creams / Gels

05. Others (Drugs)

06. Surgicals (Specify item names)

07. Sutures (Specify types)

08. Implants

09. Devices

Signature :

Date :

Name of the Lab :

Office Seal :

ANNEXURE – IV (a)
Ref. Clause No: 3 (j) (a)

PERSONNEL IN QC DEPARTM ENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drugs/surgical/sutures)

Signature :

Date :

Nam e of the Lab :

Office Seal :

ANNEXURE – IV (b)
Ref. Clause No: 3(j) (b)

LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS AVAILABLE IN THE LAB

S.No.	Name of the Equipment Instruments / Apparatus	Make & Description	Date of Installation	Date of last Validation	Approved for testing of drugs from State licensing Authority since……..

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (C)
Ref. Clause No: 3(j) (c)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (d)
Ref. Clause No: 3(j) (d)

LISTOF REFERENCES SAMPLES ALONG WITH THEIR DATE OF PROCUREMETN AND QUANTITIES

Signature :

Name of the Lab :

Date :

Official Seal:

Affidavit
(on Non Judicial Stamp of Rs.100/-)

ANNEXURE – V
Ref. Clause No: 3(k)

DECLARATION FORM

1. I (Name of the Bidder) S/O_____, Age_____, resident of_____, am proprietor /Partner/Director having our office at_____ and the approved drug testing laboratory at_____do hereby declare that I have carefully read all the conditions of BID of Rajasthan Medical Services Corporation Ltd., Jaipur, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs. (ending on 31.12.2015) and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drugs/surgicals & sutures for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drugs/surgical & sutures have been obtained on Form 37 bearing No._____which is valid/renewed up to_____.
4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the other partners/directors:-

S.No.	Name of Partner/Director	Age	Present & Permanent Address

5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.
6. Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of wrong reporting of test results or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.

7. That i/we have carefully read all the conditions of bid in Ref. No.: F.02(63)/RMSCL/ED (P) EMPANELMENT/DTL/NIB -10/2013/ 1170 dated 01.11.2013 for the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Ending on 31.12.2015) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.

8. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
    a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
    b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
    c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
    d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
    e. l/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;
9. Our complete address for communication with phone no.:- ----------
---

----------Pin code----------

10. E=mail address :- ----------
11. Bank detail for e banking :-

Name of account holder ……

Full name of Bank with Branch ……

A/c no. with full digits……..

IFSC code ……..

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

I……..S/o……(Designation)……. Affirm on oath that the contents/information from para 1 to 10 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting the earnest money deposit and or performance security, for which I shall be solely responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)

ATTESTED BY NOTARY PUBLIC

ANNEXURE – VI
Ref.Clause No: 3 (l)

DETAILS OF LABORATORY

1. Name of the Laboratory & Full Address :

   Phone No (landline) :

   Fax :

   E-mail :

2. Other Branches & their Address (if any) :

3. Whether the firm has it own manufacturing unit? :

   If yes give details of address, license number etc.

4. Date of Inception :

5. Approval No. & Date :

6. Issued by :

7. Valid up to :

8. Schedule L-1 certificate its no. and date of issue :

9. (i) NABL Accreditation no. & date
   (ii) Scope of Accreditation
   (iii) Its validity.

10. Name of the authorized signatory :

11. Specimen Signature of the authorized Signatory :

12. Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports :

ANNEXURE –VII
Ref: Clause no. 3 (a),7(1)

S.N.	Code No.	Name of item with specification	Test proposed to be carried out	Remark
1.	1	Atropine Sulphate Injection IP 0.6 mg /ml (SC/IM/IV use)		
2.	2	Bupivacaine Hydrochloride in Dextrose Injection USP Each ml contains Bupivacaine Hydrochloride 5.0 mg. Dextrose 80.0 mg.		
3.	4	Bupivacaine Injection IP 0.5%		
4.	5	Drotaverine Hydrochloride Injection 40 mg/ 2 ml		
5.	6	Halothane BP		
6.	7	Isoflurane USP		
7.	8	Ketamine Injection IP 50 mg/ ml		
8.	9	Lignocaine Ointment 5%		
9.	10	Lignocaine and Adrenaline Inj. IP Each ml. Contains :- Lignocaine Hydrochloride IP 20 mg. Adrenaline IP 0.01 mg		
10.	11	Lignocaine and Dextrose Injection IP Each ml contains Lignocaine 50 mg and Dextrose (monohydrate) 75 mg		
11.	12	Lignocaine Gel IP 2%		
12.	13	Lignocaine injection IP 2%		
13.	14	Propofol Injection IP 10 mg/ ml		
14.	15	Thiopentone Injection IP 0.5 g		
15.	16	Aspirin Tablets IP 300mg		
16.	19	Diclofenac Sodium Injection IP 25 mg/ ml		
17.	20	Diclofenac Sodium Tablets IP 50 mg		
18.	21	Fentanyl Citrate Injection 50 mcg /ml		
19.	22	Ibuprofen and Paracetamol Tablets Ibuprofen 400 mg +Paracetamol 325mg		

20.	23	Ibuprofen Tablets IP 200 mg (Coated)		
21.	24	Ibuprofen Tablets IP 400 mg (Coated)		
22.	25	Morphine Sulphate Injection IP 10mg/ml		
23.	26	Paracetamol Drops (Each ml contains Paracetamol 150 mg)		
24.	27	Paracetamol Syrup IP 125mg/ 5 ml		
25.	28	Paracetamol Tablets IP 500 mg		
26.	29	Paracetamol Inj. 150mg/ml		
27.	30	Pentazocine Injection IP 30mg/ml (IM/IV Use)		
28.	31	Pethidine Hydrochloride Injection IP 50mg/ml (IM/IV use)		
29.	32	Tramadol Capsules IP 50 mg		
30.	33	Tramadol Injection 50 mg/ ml		
31.	34	Adrenaline Injection IP 1mg/ml (IM/IV use)		
32.	35	Betamethasone Tablets IP 0.5 mg		
33.	36	Cetirizine Tablets IP 10 mg		
34.	37	Chlorpheniramine Maleate Tablets IP 4 mg		
35.	39	Dexamethasone Injection IP 8 mg/2ml		
36.	40	Dexamethasone tablets IP 0.5mg		
37.	42	Hydrocortisone Sod. Succinate Injection IP 100 mg base / vial (IM/IV use)		
38.	43	Hydroxyzine Tablets 25 mg		
39.	44	Methyl Prednisolone Sodium Succinate for Injection USP 500 mg		
40.	45	Pheniramine Injection IP 22.75mg/ml		
41.	46	Hydrocortisone Sod. Succinate Injection IP (IM/IV use)		
42.	47	Prednisolone Tablets IP 5 mg		
43.	48	Promethazine Syrup IP 5 mg/ 5ml		
44.	49	Promethazine Injection IP 25mg/ ml		
45.	50	Promethazine Tablets IP 25 mg		
46.	51	Naloxone Injection IP 0.4mg/ ml		
47.	52	Pralidoxime Chloride Injection IP 25 mg/ml		
48.	53	Carbamazepine Tablets IP 200 mg (Film Coated)		

49.	54	Carbamazepine Tablets IP 100 mg (Film Coated)		
50.	56	Phenobarbitone Tablets IP 30 mg		
51.	57	Phenytoin Injection 50 mg/ml		
52.	58	Phenytoin Oral suspension IP 25mg/ml		
53.	59	Phenytoin Tablets IP 100 mg (Film Coated)		
54.	60	Sodium Valproate Injection 100 mg/ ml		
55.	61	Sodium Valproate Tablets IP 200 mg (Enteric Coated)		
56.	62	Acyclovir oral Suspension USP/BP 400mg/5ml		
57.	63	Acyclovir Tablets IP 200 mg		
58.	64	Acyclovir Tablets IP 800 mg		
59.	65	Albendazole Oral suspension 400 mg/10ml		
60.	66	Albendazole Tablets IP 400 mg		
61.	67	Amikacin Injection IP 100 mg		
62.	68	Amikacin Injection IP 500 mg		
63.	69	Amoxycillin and Cloxacillin Capsules 250mg + 250 mg		
64.	70	Amoxycillin and Potassium Clavulanate Tabs IP 500 mg + 125 mg		
65.	71	Amoxycillin Capsules IP 250mg		
66.	72	Amoxycillin Capsules IP 500mg		
67.	73	Amoxycillin Dispersible Tablets IP 125mg		
68.	74	Amphotericin B Injection IP 50 mg		
69.	75	Ampicillin Injection IP 500 mg		
70.	78	Azithromycin Tablets 100 mg Dispersible Tablets		
71.	79	Azithromycin Tablets IP 250 mg		
72.	81	Benzathine Benzylpenicillin Inj IP 12 lac units		
73.	82	Benzathine Benzylpenicillin Inj IP 6 lac units		
74.	83	Benzyl Penicillin Injection IP 600 mg Benzylpenicillin /Vial (10 Lac units)		
75.	84	Cefixime Tablets IP 100 mg		
76.	85	Cefixime Tablets IP 200 mg		
77.	86	Cefoperazone and Sulbactum for Injection Cefoperazone Sodium eq. to Cefoperazone 1 g and Sulbactum Sodium eq. to Sulbactum 0.5 g (IM/ IV use)		
78.	87	Cefotaxime Injection 1g		
79.	88	Cefotaxime Injection IP 250 mg		
80.	89	Ceftazidime Injection IP 1 g		

81.	90	Ceftazidime Injection IP 250 mg		
82.	91	Ceftazidime Injection IP 500 mg		
83.	92	Ceftriaxone Injection IP 125 mg		
84.	93	Ceftrioxone Injection IP 1g /vial		
85.	94	Ceftrioxone Injection IP 250 mg/ vial		
86.	95	Ceftrioxone Injection IP 500mg/vial		
87.	96	Cephalexin Capsules IP 250 mg		
88.	97	Cephalexin Capsules IP 500 mg		
89.	98	Chloroquine Phosphate Injection IP 40mg/ml		
90.	99	Chloroquine Phosphate Tab. IP 250mg (=155 mg of Chloroquine base) (Film Coated)		
91.	101	Ciprofloxacin Injection IP 200mg/100ml		
92.	102	Ciprofloxacin Tablets IP 250 mg Film Coated		
93.	103	Ciprofloxacin Tablets IP 500 mg film Coated		
94.	104	Clotrimazole Cream IP 2% w/w		
95.	105	Clotrimazole Vaginal Tablets IP 500 mg)		
96.	106	Compound Benzoic Acid Ointment IP Benzoic Acid 6%+ Salicylic Acid 3%		
97.	107	Co-trimoxazole Oral suspension IP Each 5 ml contains Trimethoprim 40 mg and Sulphamethoxazole 200 mg		
98.	108	Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg		
99.	109	Co-trimoxazole Tablets IP Trimethoprim 80 mg and Sulphamethoxazole 400 mg		
100.	110	Diethylcarbamazine Tablets IP 100 mg		
101.	111	Doxycycline Capsules IP 100 mg		
102.	112	Erythromycin Estolate Oral Suspension 125mg/5ml		
103.	113	Erythromycin Stearate Tablets 250mg		
104.	114	Fluconazole Tab. IP150mg.		
105.	116	Gentamycin Injection IP 80mg/2ml (IM/ IV use)		
106.	117	Griseofulvin Tablets IP 125 mg		
107.	118	Itraconazole Capsule 100 mg		

108.	119	Meropenem Injection IP 500 mg		
109.	120	Metronidazole Injection IP 500 mg/100ml		
110.	121	Metronidazole Benzoate Oral Suspension IP 100 mg of base/5ml		
111.	122	Metronidazole Tablets IP 200 mg (Film Coated)		
112.	123	Metronidazole Tablets IP 400 mg (Film Coated)		
113.	124	Norfloxacin Tablets IP 400 mg Film Coated		
114.	125	Ofloxacin Tablets IP 200 mg		
115.	126	Phenoxymetylpenicillin Potassium Tablets 125mg		
116.	127	Phenoxymetylpenicillin Potassium Tablets 250mg		
117.	128	Primaquine Tablets IP 2.5 mg		
118.	129	Primaquine Tablets IP 7.5 mg		
119.	130	Procaine Penicillin with Benzylpenicillin Injection IP 3+1 lac units		
120.	131	Quinine Dihydrochloride Injection 300 mg/ ml		
121.	132	Quinine sulphate Tablets IP 300mg (Film Coated)		
122.	133	Azathioprine Tablets IP 50 mg		
123.	134	Bleomycin Injection IP 15 units		
124.	135	Calcium Folinate Tablets BP/Leucovorin Calcium Tablet USP Cal. Folinate eq. to Folinic Acid /Leucovorin 15 mg		
125.	136	Chlorambucil Tablets IP 5 mg		
126.	137	Cisplatin Injection IP 50 mg/ 50 ml		
127.	138	Cyclophosphamide Injection IP 200 mg		
128.	139	Cyclophosphamide Injection IP 500 mg		
129.	140	Cyclosporin Capsules USP 25mg		
130.	141	Cytarabine Injection IP 100mg/ ml		
131.	142	Danazol Capsules IP 50 mg		
132.	143	Daunorubicin Injection IP 20 mg		
133.	144	Doxorubicin Injection IP 50 mg/ 25 ml		

134.	146	Etoposide Injection IP 100 mg/ 5 ml		
135.	147	Flunarizine Tablets 5 mg		
136.	148	Fluorouracil Injection IP 250 mg/ 5ml		
137.	149	L-Asparaginase Injection 10000 IU		
138.	150	Leucovorin Calcium Injection IP 10 mg /ml		
139.	151	Melphalan Tablets IP 5 mg		
140.	152	Mercaptopurine Tablets IP 50 mg		
141.	153	Methotrexate Injection IP 50 mg/ 2 ml		
142.	154	Methotrexate Tablets IP 2.5 mg		
143.	155	Paclitaxel Injection IP 260 mg		
144.	156	Paclitaxel Injection IP 100 mg		
145.	157	Tamoxifen Tablets IP 10 mg		
146.	158	Vinblastine Injection IP 10mg/ 10ml		
147.	159	Vincristine Injection IP 1mg/ ml		
148.	160	Levodopa and Carbidopa Tablets IP Levodopa 100 mg + Carbidopa 10 mg		
149.	161	Levodopa and Carbidopa Tabs IP 250 mg + 25 mg		
150.	162	Trihexyphenidyl Hydrochloride Tablets IP 2 mg		
151.	163	Acenocoumarol Tablets IP 2 mg		
152.	165	Deferasirox Tablets 100 mg		
153.	166	Deferasirox Tablets 500 mg		
154.	167	Deferiprone Capsules 250 mg		
155.	168	Deferiprone Capsules 500 mg		
156.	169	Desferrioxamine Injection IP 500 mg / Vial (For I.M. Inj and I.V., S.C. Infusion)		
157.	171	Dried Human Anti haemophlic Fraction IP (Dried Factor VIII Fraction IP) 250 IU/ Vial (IV use)		
158.	172	Enoxaparin Sodium Injection IP 60 mg		
159.	173	Ethamsylate Injection 250 mg/ 2 ml (IM/ IV)		
160.	174	Heparin Sodium Injection IP 5000 IU/ ml (IM/ IV use)		
161.	175	Human Albumin Solution IP 20%		
162.	176	Rh-Erythropoetin Injection 10000 IU		
163.	177	rh-Erythropoetin Injection 2000IU		

164.	179	Rh-Erythropoetin Injection 4000 IU		
165.	180	Vitamin K Injection Each ml Contains Menadione Sodium Bisulphite 10mg Equivalent to 5.2 mg of Menadione. (Aqueous Solution)		
166.	181	Amiodarone Tablets IP 100 mg		
167.	182	Amiodarone Tablets IP 200 mg		
168.	183	Amiodarone Hydrochloride Injection 50 mg/ ml		
169.	184	Amlodipine Tablets IP 2.5 mg		
170.	185	Amlodipine Tablets IP 5 mg		
171.	186	Atenolol Tablets IP 50 mg		
172.	187	Atorvastatin Tablets IP 10mg		
173.	188	Clopidogrel Tablets IP 75 mg		
174.	189	Digoxin Injection IP 0.25 mg/ml		
175.	190	Digoxin Tablets IP 0.25 mg.		
176.	191	Diltiazem Tabs IP 30 mg Film Coated		
177.	192	Dobutamine Injection 50 mg/ml		
178.	193	Dopamine Hydrochloride Injection 40 mg/ml		
179.	194	Enalapril Maleate Tablets IP 5mg		
180.	195	Enalapril Maleate Tablets IP 2.5 mg		
181.	196	Glyceryl Trinitrate Tablets IP 2.6 mg		
182.	197	Isosorbide dinitrate Tablets IP 5 mg		
183.	198	Isosorbide mononitrate Tabs IP 20 mg		
184.	199	Lisinopril Tablets IP 5 mg		
185.	200	Losartan Tablets IP 50 mg		
186.	201	Magnesium Sulphate Injection 50 mg/ml (50% w/v)		
187.	202	Methyldopa Tablets IP 250mg Film Coated		
188.	203	Nifedipine capsules IP 5mg		
189.	204	Nifedipine Tablets IP 10 mg. (Sustained Release)		
190.	205	Nitroglycerin Injection 5 mg/ ml		
191.	207	Propranolol Tablets IP 40 mg		
192.	209	Streptokinase Injection IP 15 lac units		
193.	211	Verapamil Tablets IP 40 mg Film Coated		
194.	212	Verapamil Injection IP 2.5 mg/ ml		
195.	213	Acyclovir Cream BP 5%		
196.	217	Glycerin IP		
197.	218	Liquid Paraffin IP		
198.	219	Ointment containing: Lidocaine IP 3%, Zinc oxide IP 5%, Hydrocortisone IP 0.25%, Allantoin IP 0.5%		
199.	220	Miconazole Nitrate Cream IP 2%		

200.	221	Povidone Iodine Ointment 5%		
201.	222	Povidone Iodine solution IP 5%		
202.	223	Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg)		
203.	224	Silver Sulphadiazine cream 1%		
204.	225	Anti A Blood Grouping Serum **(Anti A Monoclonal Serum)**		
205.	226	Anti B Blood Grouping Serum **(Anti B Monoclonal Serum)**		
206.	227	Anti DRH Blood Grouping Serum		
207.	229	Barium sulphate suspension IP 100%		
208.	232	Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 60% (iodine conc = 292 mg/ml)		
209.	233	Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 76%w/v (iodine conc = 370 mg/ml)		
210.	234	Fluorescein Eye Drops IP 1%		
211.	235	Gadodiamide Inj. 0.5 mmol/ml Vial		
212.	236	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml.		
213.	238	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 240 mg Iodine/ml		
214.	239	Mantoux Fluid (Tuberculin PPD IP)		
215.	240	Subgroup for Serum A (Anti-A1 Lectin)		
216.	241	Tropicamide Eye Drops IP 1%		
217.	242	VDRL Antigen (with +ve and- ve control)/ RPR Slide Kit		
218.	243	Cetrimide Tincture 0.5% w/v (Cetrimide 0.5 w/v, Average Absolute Alcohol content 65.5% v/v)		
219.	244	Compound Benzoin Tincture IP		
220.	245	Formaldehyde Solution IP		
221.	246	Gentian Violet Topical Solution USP 1%		
222.	247	Gluteraldehyde solution IP 2 %		
223.	248	Hydrogen Peroxide Solution IP 6% (20 ml)		
224.	249	Lysol (Cresol with Soap Solution) IP Cresol 50% + Soap 50%		
225.	250	Povidone Iodine Scrub Solution / cleansing solution 7.5% w/v Povidone Iodine (suitable for hand wash)		
226.	252	Surgical Spirit BP		
227.	253	Acetazolamide Tablets IP 250mg		

228.	254	Frusemide Tablets IP 40 mg		
229.	255	Furosemide Injection IP 10mg/ml (IM & IV use)		
230.	256	Hydrochlorthiazide Tablets IP 12.5 mg		
231.	258	Spironolactone Tablets IP 25 mg		
232.	259	Torsemide Tablets 10 mg		
233.	262	Bisacodyl Tablets IP 5 mg		
234.	263	Dicyclomine Tablets IP 10 mg		
235.	264	Dicyclomine Injection IP 10 mg /ml		
236.	265	Dicyclomine Hydrochloride Oral Solution IP 10mg /5ml		
237.	266	Domperidone Suspension 5 mg/5ml		
238.	267	Domperidone Tablets IP 10 mg		
239.	268	Hyoscine Butylbromide Injection IP 20 mg/ml		
240.	269	Loperamide Tablets IP 2 mg		
241.	270	Metoclopramide Injection IP 10mg/2ml		
242.	271	Metoclopramide Tablets IP 10 mg		
243.	272	Omeprazole Capsules IP 20 mg		
244.	273	Ondansetron Injection IP 2mg/ml		
245.	274	ORS Powder IP		
246.	275	Pentoprazole Injection 40 mg		
247.	276	Ranitidine HCL Injection IP 50mg/2ml		
248.	277	Ranitidine Tablets IP 150mg Film coated		
249.	278	Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10%, Disodium Hydrogen Phosphate Dodecahydrate 8%		
250.	279	Biphasic Isophane Insulin Injection IP (30% Soluble Insulin & 70% Isophane Insulin) Inj 40 IU/ml (r-DNA origin)		
251.	280	Carbimazole Tabs IP 5 mg (film Coated)		
252.	281	Carboprost Tromethamine Injection Each ml contains Carboprost 0.25mg/ml		
253.	282	Clomifene Tablets IP 25 mg		
254.	283	Clomiphene Tablets IP 50 mg		
255.	284	Conjugated Estrogen Tabs USP 0.625 mg.		
256.	285	Dinoprostone Cream/Gel 0.5 mg Dinoprostone in syringe		
257.	286	Ethinyloestradiol Tabs IP 50 mcg		
258.	287	Glibenclamide Tablets IP 5 mg		
259.	288	Gliclazide Tablets IP 40 mg		
260.	289	Glimepiride Tablets IP 2 mg		
261.	290	Glimepiride Tablets IP 1 mg		

262.	291	Glipizide Tablets IP 5mg		
263.	293	Hydroxyprogesterone Injection IP 250mg/ ml		
264.	294	Isophane Insulin Injection IP 40 IU/ml		
265.	295	Metformin Tablets IP 500 mg. (Film Coated-Scored)		
266.	296	Norethisterone Tablets IP 5 mg		
267.	297	Pioglitazone Tablets IP 15 mg		
268.	298	Progesterone Injection 200 mg/ 2ml		
269.	299	Propylthiouracil Tablets IP 50 mg		
270.	300	Soluble Insulin Injection IP 40 IU/ ml. (r-DNA origin)		
271.	301	Thyroxine Sodium Tablets IP 0.1 mg of Thryoxine Sodium equivalent to 0.091 mg of anhydrous Thyroxine Sodium		
272.	302	Human Anti D Immunoglobulin IP Inj. 50mcg		
273.	303	Human Anti D Immunoglobulin Injection 300mcg (I.M.use)		
274.	304	Human Anti D Immunoglobulin IP 150 mcg		
275.	305	Human Anti Rabies Immunoglobulin Injection 150 IU/ ml		
276.	306	Rabies Vaccine Human (Cell Culture) IP (Intradermal) 2.5 IU		
277.	307	Rabies Vaccine Human (Cell Culture) IP (Intramuscular) 2.5 IU/ dose		
278.	308	Snake Venum Anti Serum IP (Lyophilized) Polyvalent Anti Snake Venum, Serum Enzyme Refined. Contain purified equine globulins. 1 ml of serum neutralizes 0.6 mg of cobra venum, 0.45 mg of common kraite (Bungaras) venum.		
279.	309	Tetanus Immunoglobulin 250 IU/ Vial		
280.	310	Tetanus Vaccine (adsorbed) IP		
281.	311	Atracurium Injection USP 10 mg/ ml		
282.	312	Glycopyrrolate Injection USP 0.2 mg/ml		
283.	313	Midazolam Injection BP 1 mg/ ml		
284.	314	Neostigmine Injection IP 0.5 mg/ml		
285.	316	Neostigmine Tablets IP 15 mg		
286.	317	Succinylcholine Injection IP 50 mg/ml (IV use)		
287.	318	Valethamate Bromide Injection 8mg / ml		
288.	319	Atropine Eye Ointment IP 1%		
289.	320	Atropine Sulphate Ophthalmic Solution USP 1%		
290.	321	Chloramphenicol Eye Drops 0.5%		
291.	322	Ciprofloxacin Eye Drops 0.3 % w/v		

292.	323	Ciprofloxacin Ophthalmic Ointment USP 0.3%		
293.	324	Hydroxypropylmethyl cellulose Solution 20 mg/ ml		
294.	326	Pilocarpine Eye Drops IP 2%		
295.	328	Sulfacetamide Eye drops 20%		
296.	329	Timolol Eye Drops IP 0.25% w/v		
297.	330	Tobramycin and Dexamethasone Ophthalmic Suspension USP 0.3%+0.1%		
298.	331	Tobramycin Eye Drops 0.3%		
299.	332	Tobramycin Ophthalmic Ointment USP 0.3%		
300.	333	Isoxsuprine Injection IP 5 mg/ml		
301.	334	Isoxsuprine Tablets IP 20 mg		
302.	335	Methylergometrine Injection IP 0.2 mg/ml		
303.	336	Methylergometrine Tablet IP 0.125 mg		
304.	337	Misoprostol Tablets 200 mcg		
305.	338	Oxytocin Injection IP 5 IU/ml		
306.	339	Alprazolam Tablets IP 0.25 mg		
307.	340	Alprazolam Tablets IP 0.5 mg		
308.	341	Amitriptyline Tablets IP 25 mg Film Coated		
309.	342	Chlordiazepoxide Tablets IP 10mg		
310.	343	Chlorpromazine Tablets 100 mg (Coated Tablet)		
311.	344	Chlorpromazine Tablets IP 25 mg (Coated Tablet)		
312.	345	Chlorpromazine Tablets IP 50 mg (Coated Tablets)		
313.	346	Chlorpromazine Inj. IP 25mg/ml		
314.	347	Clomipramine Capsules IP 25 mg		
315.	348	Clonazepam Tablets IP 1 mg		
316.	349	Diazepam Injection IP 10mg/2ml (1M/IV use)		
317.	350	Diazepam Tablets IP 5 mg		
318.	351	Escitalopram Tablets 10 mg		
319.	352	Fluoxetine Capsules IP 20 mg		
320.	353	Haloperidol Injection IP 5 mg/ml		
321.	354	Haloperidol Tablets IP 1.5 mg		
322.	355	Haloperidol Tablets IP 5 mg		
323.	356	Imipramine Tablets IP 25 mg (Coated Tablets)		
324.	357	Imipramine Tablets IP 75 mg (Coated)		
325.	358	Lithium Carbonate Tablets IP 300 mg		
326.	359	Lorazepam Injection 2 mg/ ml		
327.	360	Olanzapine Tablets IP 5 mg		
328.	361	Risperidone Tablets 2 mg		
329.	362	Risperidone Tablets 1 mg		

330.	363	Sertraline Tablets 50 mg		
331.	364	Trifluperazine Tablets IP 5 mg Coated		
332.	365	Aminophylline Injection IP 25 mg/ml		
333.	366	Beclomethasone Inhalation IP 200 mcg/ dose		
334.	367	Budesonide Nebulizer Suspension 0.25mg/ ml		
335.	368	Cough Syrup Each 5ml contains Chloropheniramine Maleate IP 3mg Ammonium Chloride 130mg, Sodium Citrate 65 mg, Menthol 0.5 mg, Syrup Q.S.		
336.	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ ml		
337.	370	Salbutamol Tablets IP 4 mg		
338.	371	Salbutamol Inhalation 100 mcg /dose		
339.	372	Salbutamol Nebuliser Solution BP 5 mg/ ml		
340.	373	Salbutamol Tablets IP 2 mg		
341.	374	Theophylline and Etofylline Injection (Anhydrous Theophylline 50.6mg + Etofylline 169.4 mg)		
342.	375	Theophylline and Etofylline Tablets (Theophylline IP 23mg + Etofylline IP 77 mg)		
343.	376	Theophylline Tablets 400 mg (Sustained Release/ Controlled Release)		
344.	377	Compound Sodium Lactate inj. IP		
345.	378	Dextrose Injection IP 25 % w/v		
346.	379	Dextrose injection 10%		
347.	380	Dextrose injection 5% isotonic		
348.	381	Multiple Electrolytes & Dextrose Injection Type I IP (Electrolyte 'P' Injection)		
349.	382	Multiple Electrolytes & Dextrose Injection Type III IP Electroylte "M" Injection (I.V.)		
350.	383	Potassium Chloride Injection 0.15 gm/ml		
351.	384	Potassium chloride Oral Solution U.S.P 500mg/ 5ml		
352.	385	Sodium Chloride and Dextrose Inj. I.P (0.9%+5%)		
353.	386	Sodium Chloride Injection IP		
354.	387	Ascorbic Acid Tablets IP 500 mg		
355.	388	Calcium Gluconate Injection IP 10% (IV use)		
356.	390	Ferrous Sulphate with Folic Acid Tab. Each film coated Tab. Containing Dried Ferrous Sulphate IP- equivalent to 100 mg Elemental Iron and Folic Acid IP 0.5 mg		
357.	391	Ferrous Sulphate with Folic Acid Tab. (Paediatric) Each film coated Tab. Containing		

		dried Ferrous Sulphate IP-equivalent to 20 mg Elemental Iron and Folic Acid IP-100		
358.	392	Folic Acid Tablets IP 5 mg		
359.	393	Multivitamin Drops Each ml contains Vit-A -3000 IU, Vit-D3-300 IU, Vit-B1 -1mg, Riboflavine Phosphate Sodium -2mg, D-Panthenol -2.5mg, Niacinamide -10mg, Pyridoxine HCL-1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg		
360.	394	Multivitamin Tablets NFI Formula Sugar coated. Vit A 2500 IU, Vit B1-2mg, Vit- B6-0.5mg, Vit-C-50mg, Calcium Pantothenate-1mg, Vit-D3-200IU, Vit-B2 2 mg, Niacinamide-25mg, Folic Acid-0.2 mg		
361.	395	Vitamin B Complex Injection NFI		
362.	397	Vitamin – B complex tablet NFI(prophylactic) B1- 2mg, B2- 2mg, B6-0.5mg, Niacinamide 25mg, Calcium pantothenate 1mg (With appropriate overages)		
363.	398	Black Disinfectant Fluid (Phenyl) (As per Schedule "O" Grade – III		
364.	399	Concentrated Haemodialysis Fluid B.P Acetate concentrate in 10 Litre Cans. Each 1000ml After 1:34 dilutions should provide Sodium Chloride 135 to 140 meq/Litre sodium Acetate 35-38 meq/Litre Potassium Chloride 1.5-2 meq/Litre Magnesium chloride 1-1.5 meq/Litre calcium chloride 0-3 meq/Litre (depending on local condition) water purified to 1000 ml		
365.	401	Peritonial Dialysis Solution IP		
366.	402	Sodium Bicarbonate Injection IP 7.5% w/v		
367.	404	Water for Injection IP		
368.	405	Polygeline 3.5% Solution with electrolytes for IV Infusion		
369.	406	Factor- IX Concentrate (Purified) 600 IU (Human Coagulation Factor IX)		
370.	407	Anti-Inhibitor coagulation Complex (Human Plasma Protein with a Factor VIII Inhibitor Bypassing Activity of 500 IU per Vial)		
371.	408	Rabies Antiserum IP (Equine) 300 units per ml [contains equine anti-rabies immunoglobulin fragments](I.M./SC use)		
372.	409	Vitamin A Paediatric oral solution IP Vitamin A Concentrate Oil IP Each ml		

		contains vitamin A 100000 IU		
373.	410	Labetalol Tablets IP 100mg		
374.	411	Labetalol Hydrochloride Injection BP/USP 20mg/4ml		
375.	412	Ampicillin Capsules IP 500 mg		
376.	413	Nitrofurantoin Tablets IP 100mg		
377.	414	Hyoscine Butyl Bromide Tablets IP 10mg (Coated Tablets)		
378.	415	Drotaverine Tablets 40 mg		
379.	416	Hydroxyethyl Starch (130/0.4) 6% w/v with Sodium Chloride 0.9% w/v Intravenous Infusion		
380.	417	Cloxacillin sodium Injection IP 500 mg		
381.	418	Betamethasone Sodium Phosphate Injection IP 4 mg/ml		
382.	419	Vecuronium Bromide for Injection 4 mg (Freeze Dried)		
383.	420	Phenobarbitone Injection IP 200mg/ml		
384.	421	Flurbiprofen Sodium Ophthalmic Solution USP 0.03% w/v		
385.	423	Hyaluronidase Injection IP Each vial contains Hyaluronidase IP 1500 IU		
386.	424	Lidocaine Hydrochloride Topical Solution USP 4%		
387.	425	Fluconazole Eye Drops 0.3%		
388.	426	Co-trimoxazole Tablets P (Trimethoprin 20 mg and Sulphamethoxazole 100mg		
389.	427	Cephalexin Oral Suspension IP (Cephalexin Dry Syrup IP) 125 mg/ 5 ml		
390.	428	Ofloxacin Suspension 50mg/ 5ml		
391.	429	Furazolidone Tablets IP 100 mg		
392.	430	Tinidazole Tablets IP 300 mg (Film Coated)		
393.	431	Tinidazole Tablets IP 500 mg (Film Coated)		
394.	432	Salbutamol Syrup IP 2mg/ 5ml		
395.	433	Ranitidine Tablets IP 300 mg Film coated		
396.	434	Famotidine Tablets IP 20 mg		
397.	435	Famotidine Tablets IP 40 mg		
398.	436	Indomethacin Capsules IP 25 mg		
399.	437	Slow Diclofenac Tablete BP / Diclofenac sodium extended release Tablet USP 100 mg (sustained release)		
400.	438	Dicyclomine Hydrochloride and Activated dimethicone suspension. Each ml contains: Dicyclomine Hydrochloride 10 mg, Activated		

		dimethicone 40 mg		
401.	440	Dextromethorphan Hydrobromide Syrup IP 13.5mg / 5ml		
402.	441	Calcium & Vitamin D3 Suspension (Each 5 ml contains Calcium Carbonate equivalent to elemental Calcium 250 mg, Vitamin D3 - 125 IU)		
403.	442	Saline Nasal Solution (Drops) (Sodium chloride 0.65%)		
404.	443	Clotrimazole mouth paint (Clotrimazole 1% w/v)		
405.	444	Aspirin Delayed Release Tablets USP. Each enteric coated tablet contains Acetyl Salicylic Acid 75 mg		
406.	445	Beclomethasone, Neomycin and Clotrimazole Cream (Beclomethasone dipropionate 0.025%, Neomycin sulphate 0.5% Clotrimazole 1%)		
407.	446	Gamma Benzene Hexachloride Lotion 1% (Lindane lotion USP)		
408.	447	Chlorhexidine Gluconate Solution IP 5%		
409.	448	Iron and Folic Acid Syrup. Each 5ml contains Ferrous Fumerate 100mg, Folic Acid 500 mcg		
410.	449	Surgical Spirit BP		
411.	450	Povidone Iodine Solution IP 5%		
412.	451	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg		
413.	452	Glipizide and Metformin Hydrochloride tablets USP (Glipizide 5mg, Metformin Hydrochloride 500 mg)		
414.	453	Glibenclamide and Metformin Hydrochloride (SR) Tablets [Glibenclamide 5mg, Metformin Hydrochloride 500 mg (Sustained Release)]		
415.	454	Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets {Metformin Hydrochloride (Sustained Release) 500 mg, Glimipiride 1 mg}		
416.	455	Metformine Hydrochloride (Sustained Release) and Glimperiride Tablets {Metformine Hydrochloride (Sustained Release) 500 m, Glimipiride 2 mg}		
417.	456	Glimperiride, Pioglitazone and Metformin Hydrochloride (Sustained Release) Tablets Each Tablet contains Glimepiride 2mg, Pioglitazone 15mg, Metformin Hydrochloride(Sustained release) 500 mg		
418.	457	Amlodipine and Enalapril Maleate Tablet (Amlodipine Besilate equivalent to Amlodipine		

		5mg, Enalapril maleate 5mg)		
419.	458	Losarton Potassium & Amlodipine tablets IP (Losarton Potassium 50 mg, Amlodipine Besilate eq. to Amlopdipine 5mg)		
420.	459	Losarton Potassium & Hydrochlorothiazide Tablets IP (Losarton Potassium 50 mg, Hydrochlorothiazide 12.5 mg)		
421.	460	Amlodipine and Lisinopril Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Lisinopril eq. to lisinopril (anhydrous) 5mg]		
422.	461	Amlodipine and AtenololTablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Atenolol 50mg]		
423.	462	Atenolol Tablets IP 25 mg		
424.	463	Enalapril Maleate Tablets IP 10 mg		
425.	464	Hydrochlorthiazide Tablets IP 25 mg		
426.	465	Lisinopril Tablets IP 10 mg		
427.	466	Lisinopril Tablets IP 2.5 mg		
428.	467	Losartan Tablets IP 25 mg		
429.	468	Piperacillin and Tazobactum for Injection USP 4 gm + 500 mg		
430.	469	Prednisolone Tablets IP 10 mg		
431.	470	Prednisolone Tablets IP 20 mg		
432.	471	Torsemide Injection 10 mg/ml		
433.	472	Zinc Sulphate Dispersible Tablets IP Elemental Zinc 10 mg		
434.	473	Amoxycillin Oral Suspension IP (Dry Syrup) 125 mg/ 5 ml		
435.	474	Carbamazepine Oral Suspension 100 mg/ 5ml		
436.	475	Cefpodoxime Dispersible Tablets 50 mg		
437.	476	Cephalexin Tablets 125 mg (Dispersible Tablets)		
438.	477	Ibuprofen Oral Suspension BP/USP 100 mg/ 5 ml		
439.	478	Metoclopramide Hydrochloride Syrup IP 5 mg/5ml		
440.	479	Sodium Valproate Oral Solution IP 200 mg / 5 ml		
441.	480	Diptttheria Antitoxin 10000 IU		
442.	481	Meropenem Injection IP 1 g		
443.	482	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml.		
444.	483	Diclofenac Sodium and Paracetamol Tablets Diclofenac Sodium 50 mg + Paracetamol 325 mg		

445.	484	Timolol Eye Drops IP 0.5 % w/v		
446.	485	Homatropine Eye Drops IP 2 %		
447.	486	Travoprost Ophthalmic Solution 0.004%		
448.	487	Brimonidine Tartrate and Timolol Maleate Eye Drops 0.15% + 0.5%		
449.	488	Iron Sucrose Injection USP (For IV Use) Eacl ml contain: Ferric hydroxide in complex with Sucrose equivalent to elemental Iron 20 mg		
450.	491	Sevoflurane		
451.	492	Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg		
452.	493	Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5%		
453.	494	Etoricoxib Tablets 60 mg		
454.	495	Etoricoxib Tablets 120 mg		
455.	496	Mefenamic Acid Tablets BP 500 mg		
456.	497	Anticold syrup: Each 5 ml contains Phenylephrine Hydrochloride 2.5 mg, Chlorpheniramine maleate 1 mg, and Paracetamol 125 mg		
457.	498	Cetirizine, Phenylephrine & Paracetamol Tablets Cetirizine 5 mg, Phenylephrine 10 mg & Paracetamol 325 mg		
458.	499	Cetirizine syrup IP 5 mg/ 5ml		
459.	500	Acetylcystine Solution USP (Injection) 200 mg/ ml		
460.	501	Activated Charcoal Tablet 250 mg		
461.	502	Acyclovir Intravenous Infusion IP 250 mg		
462.	503	Acyclovir Intravenous Infusion IP 500 mg		
463.	504	Amikacin Injection IP 250 mg		
464.	505	Amoxicillin and Potassium Clavulante Injection IP 600 mg		
465.	506	Amoxicillin and Potassium Clavulante Injection IP 1.2 g		
466.	507	Amoxicillin and Potassium Clavulante Oral Suspension IP 200 mg + 28.5 mg per 5 ml		
467.	508	Artesunate Injection 60 mg		
468.	509	Aztreonam Injection USP 500 mg		
469.	510	Cefepime Injection IP 500 mg		
470.	511	Cefixime Oral Suspension IP 25 mg/ ml (Paediatric Drops)		
471.	512	Cefuroxime Axetil Tablets IP 250 mg		
472.	513	Clindamycin Capsules IP 150 mg		

473.	514	Clindamycin Capsules IP 300 mg		
474.	515	Levofloxacin Tablets IP 250 mg		
475.	516	Linezolid Tablets IP 600 mg		
476.	517	Linezolid Injection 200 mg/ 100 ml		
477.	518	Mefloquine Tablets IP 250 mg		
478.	519	Metronidazole & Norfloxacin suspension 100 + 100 mg per 5 ml		
479.	520	Ofloxacin and Ornidazole Tablets (Ofloxacin 200 mg and Ornidazole 500 mg)		
480.	521	Ofloxacin Infusion IP 200mg/ 100 ml (in NaCl Inj)		
481.	522	Pyrimethamine and Sulphadoxine Tablets IP (Pyrimethamine 37.5 mg and Sulphadoxine 750 mg)		
482.	523	Vancomycin for Intravenous Infusion IP 500 mg		
483.	524	Vancomycin for Intravenous Infusion IP 1 g		
484.	525	Alpha Interferon Injection (Interferon Alpha-2 concentrated Solution IP) 3 million unit		
485.	526	Carboplatin Injection 150 mg USP/ BP		
486.	527	Carboplatin Injection 450 mg USP/ BP		
487.	528	Cisplation Injection IP 10 mg/ 10 ml		
488.	529	Dacarbazine Injection 500 mg USP/ BP		
489.	530	Filgrastim Injection (Granulocyte Colony Stimulation Factor) 300 mcg		
490.	531	Gemcitabine for Injection USP 200 mg		
491.	532	Gemcitabine for Injection USP 1 gm		
492.	533	Ifosfamide Injection USP/ BP 1 gm		
493.	534	Imatinib Tablets 400 mg		
494.	535	Mesna Injection 200 mg		
495.	536	Methotrexate Tablets IP 10 mg		
496.	537	Mitomycine for Injection USP 10 mg		
497.	538	Oxaliplatin Injection USP 50 mg		
498.	539	Bromocriptine Tablets IP 1.25 mg		
499.	540	Bromocriptine Tablets IP 2.5 mg		
500.	541	Betahistine Tablets IP 8 mg		
501.	542	Betahistine Tablets IP 16 mg		
502.	543	Cinnarizine Tablets IP 25 mg		
503.	544	Cinnarizine Tablets IP 75 mg		
504.	545	Tranexamic Acid Tablets BP 500 mg		
505.	546	Warfarin Sodium Tablets IP 5 mg		
506.	547	Adenosine Injection USP 6 mg/ 2 ml		
507.	548	Atorvastatin Tablets IP 40 mg		

508.	549	Clopidogrel and Aspirin Tablets Clopidogrel 75 mg and Aspirin 75 mg		
509.	550	Fenofibrate Capsules IP 200 mg		
510.	551	Isoprenaline Injection IP 2 mg/ml		
511.	552	Metoprolol Tablets IP 25 mg		
512.	553	Metoprolol Suscinate Extended Release Tablets USP 50 mg		
513.	554	Noradrenaline Injection IP 2 mg/ ml		
514.	555	Prazosin Tablets (Extended Release) 2.5 mg		
515.	556	Telmisartan Tablets IP 40 mg		
516.	557	Urokinase Injection 5 Lac Unit (Lyophilized)		
517.	558	Betamethasone Dipropionate Cream IP 0.05%		
518.	559	Betamethasone Lotion IP 0.05%		
519.	560	Clindamycin Phosphate Gel USP 1%		
520.	561	Clobetasol Propionate Cream USP/ BP 0.05%		
521.	562	Coal tar 4.25% and Salicylic Acid 2% Solution		
522.	563	Dithranol Ointment IP 0.5%		
523.	564	Glycerin IP		
524.	565	Ketoconazole Cream 2%		
525.	566	Neomycin sulphate and Bacitracin ointment USP 5 mg + 500 IU/ gm		
526.	567	Permethrin Lotion 1%		
527.	568	Permethrin Lotion 5%		
528.	569	Permethrin Cream 5%		
529.	570	Tretenoin Cream USP 0.025%		
530.	571	Povidone Iodine Ointment USP 5%		
531.	572	Povidone Iodine Solution IP 10%		
532.	573	Silver Sulphadiazine Cream USP 1%		
533.	574	Spironolactone Tablets IP 50 mg		
534.	575	Finasteride Tablets IP 5 mg		
535.	576	Tamsulosin HCI Tablets 0.4 mg		
536.	577	Terazosin Tablets USP 1 mg		
537.	578	Terazosin Tablets USP 2 mg		
538.	579	Flavoxate Tablets USP/ BP 200 mg		
539.	580	Chlorhexidine Mouthwash BP 0.2% / Chlorhexidine Oral rinse USP 0.2%		
540.	581	Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel base)		
541.	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)		
542.	583	Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1%		

543.	584	Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel		
544.	585	Ciprofloxacin 0.3% and Dexamethasone 0.1% Ear Drops Ciprofloxacin and Dexamethasone Otic Suspension USP		
545.	586	Clotrimazole 1% with Beclomethasone Dipropionate 0.025% Ear Drops		
546.	587	Clotrimazole 1% with lignocaine 1% Ear Drops		
547.	588	Neomycin, Polymixin B and Hydrocortisone Ear Drops (Neomycin sulphate 3400 IU, Polymixin B Sulphate 10000 IU, and Hydrocortisone 10 mg per ml) Neomycin and Polymixin B Sulfate and Hydrocortisone Otic Solution USP		
548.	589	Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15%		
549.	590	Domeperidone Oral Drops 10 mg/ ml		
550.	591	Drotaverine & Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg		
551.	592	Lactic Acid Bacillus Tablets 60 million spores		
552.	593	Lactulose solution USP/ BP 10 gm/ 15 ml or 3.35gm/5 ml		
553.	594	Liquid Paraffin IP		
554.	595	Ondansetron Orally Disintegrating Tablets IP 4 mg		
555.	596	Pantoprazole 40 mg and Domperidone 30 mg SR Capsules Pantopazole as enteric coated pellets, and Domperidone as sustained release pellets		
556.	597	Ursodeoxycholic Acid Tablets BP 300 mg		
557.	598	Allopurinol Tablets IP 100 mg		
558.	599	Hydroxychloroquine Sulphate Tablets USP/ BP 200 mg		
559.	600	Leflunomide Tablets USP 10 mg (Film coated)		
560.	601	Leflunomide Tablets USP 20 mg (Film coated)		
561.	602	Sulfasalazine Delayed Release Tablets USP/ Gastroresistant Sulfasalazine Tablets BP 500 mg		
562.	603	Gliclazide and Metformin Tablets Gliclazide 80 mg and Metformin Hydrochloride 500 mg		
563.	604	Glucagon for Injection USP 1 mg/ ml		
564.	605	Medroxyprogesterone acetate Tablets IP 10 mg		
565.	606	Testosterone Propionate Injection IP 25 mg/ 1 ml		
566.	607	Thyroxine Tablets IP 50 mcg		
567.	608	Octreotide Injection 50 mcg/ ml		
568.	609	Chlorzoxazone Tablets USP 250 mg		
569.	610	Chlorzoxazone , Diclofenac Sodium &		

		Paracetamol Tablets (Chlorzoxazone 250 mg, Diclofenac Sodium 50 mg & Paracetamol 325 mg)		
570.	611	Betaxolol Ophthalmic Solution USP / Betaxolol Eye Drops, Solution BP 0.25%		
571.	612	Betaxolol Ophthalmic Solution USP/ Betaxolol eye Drops, Solution BP 0.5%		
572.	613	Carboxymethylcellulose Sodium Lubricant Eye Drops 0.5%		
573.	614	Phenylephrine Hydrochloride Ophthalmic Solution USP/ Phenylephrine Eye Drops BP 5%		
574.	615	Mifepristone Tablets 200 mg		
575.	616	Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg		
576.	617	Budesonide Powder for Inhalation BP 200 mcg		
577.	618	Ipratropium Powder for Inhalation IP 40 mcg		
578.	619	Terbutaline Tablets IP 2.5 mg		
579.	620	Xylometazoline Nasal Drops IP 0.1 %		
580.	621	Sodium Chloride Injection IP		
581.	622	Calcium Carbonate & vitamin D3 Tablets (Elemental Calcium 500 mg, Vitamin D3- 250 IU) Calcium with Vitamin D Tablets USP/ Calcium and Colecalciferol Tablets BP		
582.	623	Cholecalciferol granules 60, 000 IU/ gm		
583.	624	Mecobalamin Injection 500 mcg/ ml		
584.	625	Nicotinamide Tablets IP 50 mg		
585.	626	Pyridoxine Tablets IP 10 mg		
586.	627	Pyridoxine Tablets IP 40 mg		
587.	628	Riboflavin Tablets IP 5 mg		
588.	629	Thiamine Tablets IP 100 mg		
589.	630	Calcitriol Capsules IP 0.25 mcg		
590.	631	Alendronate Sodium Tablets USP/ BP 35 mg		
591.	632	Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion)		
592.	633	Normal Human Intravenous Immunoglobulin 5 g/ 100 ml		
593.	634	Pregabalin Capsules IP 75 mg		
594.	635	Surfactant for intratrecheal instillation (natural bovine lung surfactant)		
595.	636	Ramipril Tablet IP 2.5 mg		
596.	637	Vitamin –A Capsule USP, Soft Gelatin Capsule contains Vit-A 50000 units		
597.	638	Neostigmine Injection IP 2.5mg/5 ml		
598.	100A	Chloroquine Suspension IP 50 mg/5ml		

599.	214A	Calamine Lotion IP		
600.	215A	Certimide Cream IP		
601.	216A	Fusidic Acid Cream IP 2%		
602.	231A	**Diagnostic Sticks for Urine Sugar and Albumin**		
603.	257A	Mannitol Injection IP 20% w/v		
604.	260A	Antacid Tablets. Formula: Each chewable tablet contains Magnesium Trisilicate 250mg, Dried Aluminium Hydroxide Gel 120mg, Peppermint oil		
605.	261A	Antacid Liquid, Each 5 ml contains Dried Aluminium Hydroxide Gel 250 mg, Magnesium Hydroxide 250 mg, Activated polydimethyl siloxane 50 mg		
606.	439A	Dicyclomine and Paracetamol Tablets Dicyclomine Hydrochloride 20 mg + Paracetamol 325 mg Tablets		
607.	80A	Azithromycin Tablets IP 500 mg		
608.	489P	IRON AND FOLIC ACID TABLETS (IFA – WIFS) Each enteric coated tablet contains: Dried Ferrous Sulphate IP equivalent to Ferrous iron 100 mg Folic Acid IP 0.5 mg The tablets are Blue coloured (Indigo Carmine)		
609.	490P	IRON AND FOLIC ACID TABLETS (IFA – Small) Each enteric coated tablet contains: Dried Ferrous Sulphate IP equivalent to Ferrous iron 30 mg Folic Acid IP 250 mcg The tablets are Blue coloured (Indigo Carmine)		
610.	0	Donepezil Tablets 5 mg		
611.	0	Baclofen Tablets 10 mg		
612.	0	Docetaxel Injection 20, 80, 120 mg		
613.	0	Insulin Glargine 100 IU/ml		
614.	0	Nicotine Gum Tablets 2, 4 mg		
615.	0	Bupropion Tablets 150 mg		
616.	0	Antimalarial ACT Combi pack containing Artesunate Tablets and Sulphadoxine + Pyremethamine Tablets		
617.	0	Artesunate Injection 60 mg in Combi pack form with Sodium Chloride Injection IP 0.9% w/v and Sodium bicarbonate Injection IP 5% w/v		
618.	0	Sterility Test alone of any product		